Therapeutic effect of fosfomycin against interstinal infection with Escherichia coli O157: H7 in a mouse model

I. Kobayashi, H. Muraoka, K. Matsuzaki, T. Saika, M. Nishida, H. Akita, S. Iwata, Y. Sato, K. Sunakawa

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The therapeutic effect of fosfomycin at a large oral dose against intestinal infection with Escherichia coli O157: H7 was investigated in a mouse model previously described. Three ICR strain (IQI, germ free) mice aged 5 weeks were challenged orally with a verotoxin-producing strain NK2 of E. coli O157: H7. The high levels of viable cells, 3.0 x 1010-3.4 x 108 CFU/g, were excreted into the feces of the untreated mice for 3-10 days after bacterial challenge. Fosfomycin was given at an oral dose of 600 mg/kg twice a day for 6 days to 3 mice infected with E. coli O157: H7, beginning 3 days after the challenge, to investigate changes in viable cell counts and to measure fecal concentrations of fosfomycin. Results were that the viable cells decreased markedly, (from about 1010 CFU/g before dosing) to 103- 104 CFU/g on day 1 of dosing, and no viable cells were detected in the feces from day 2 of dosing onwards. During the period, no verotoxin was detected in fecal samples collected from all 6 test mice (including 3 control mice). Concentrations of fosfomycin in the feces after dosing were 34.6-47.4 μg/g in all the mice on day i of dosing, and 62.4 and 131.1 μg/g in 2 of the mice on day 6 after dosing, but nondetectable otherwise. These results suggested that a marked decrease in viable cells without the liberation of verotoxin was observed in the feces of infected mice after fosfomycin was given orally in a massive dose.

Original languageEnglish
Pages (from-to)445-449
Number of pages5
JournalJapanese Journal of Chemotherapy
Volume46
Issue number11
Publication statusPublished - 1998
Externally publishedYes

Fingerprint

Fosfomycin
Escherichia coli O157
Therapeutic Uses
Infection
Shiga Toxins
Feces
Cell Count

Keywords

  • E. coli O 157: H7
  • Fosfomycin
  • Mouse Infection
  • Verotoxin

ASJC Scopus subject areas

  • Pharmacology

Cite this

Kobayashi, I., Muraoka, H., Matsuzaki, K., Saika, T., Nishida, M., Akita, H., ... Sunakawa, K. (1998). Therapeutic effect of fosfomycin against interstinal infection with Escherichia coli O157: H7 in a mouse model. Japanese Journal of Chemotherapy, 46(11), 445-449.

Therapeutic effect of fosfomycin against interstinal infection with Escherichia coli O157 : H7 in a mouse model. / Kobayashi, I.; Muraoka, H.; Matsuzaki, K.; Saika, T.; Nishida, M.; Akita, H.; Iwata, S.; Sato, Y.; Sunakawa, K.

In: Japanese Journal of Chemotherapy, Vol. 46, No. 11, 1998, p. 445-449.

Research output: Contribution to journalArticle

Kobayashi, I, Muraoka, H, Matsuzaki, K, Saika, T, Nishida, M, Akita, H, Iwata, S, Sato, Y & Sunakawa, K 1998, 'Therapeutic effect of fosfomycin against interstinal infection with Escherichia coli O157: H7 in a mouse model', Japanese Journal of Chemotherapy, vol. 46, no. 11, pp. 445-449.
Kobayashi I, Muraoka H, Matsuzaki K, Saika T, Nishida M, Akita H et al. Therapeutic effect of fosfomycin against interstinal infection with Escherichia coli O157: H7 in a mouse model. Japanese Journal of Chemotherapy. 1998;46(11):445-449.
Kobayashi, I. ; Muraoka, H. ; Matsuzaki, K. ; Saika, T. ; Nishida, M. ; Akita, H. ; Iwata, S. ; Sato, Y. ; Sunakawa, K. / Therapeutic effect of fosfomycin against interstinal infection with Escherichia coli O157 : H7 in a mouse model. In: Japanese Journal of Chemotherapy. 1998 ; Vol. 46, No. 11. pp. 445-449.
@article{fbcccce5e96a4a47b1029c8f9e901858,
title = "Therapeutic effect of fosfomycin against interstinal infection with Escherichia coli O157: H7 in a mouse model",
abstract = "The therapeutic effect of fosfomycin at a large oral dose against intestinal infection with Escherichia coli O157: H7 was investigated in a mouse model previously described. Three ICR strain (IQI, germ free) mice aged 5 weeks were challenged orally with a verotoxin-producing strain NK2 of E. coli O157: H7. The high levels of viable cells, 3.0 x 1010-3.4 x 108 CFU/g, were excreted into the feces of the untreated mice for 3-10 days after bacterial challenge. Fosfomycin was given at an oral dose of 600 mg/kg twice a day for 6 days to 3 mice infected with E. coli O157: H7, beginning 3 days after the challenge, to investigate changes in viable cell counts and to measure fecal concentrations of fosfomycin. Results were that the viable cells decreased markedly, (from about 1010 CFU/g before dosing) to 103- 104 CFU/g on day 1 of dosing, and no viable cells were detected in the feces from day 2 of dosing onwards. During the period, no verotoxin was detected in fecal samples collected from all 6 test mice (including 3 control mice). Concentrations of fosfomycin in the feces after dosing were 34.6-47.4 μg/g in all the mice on day i of dosing, and 62.4 and 131.1 μg/g in 2 of the mice on day 6 after dosing, but nondetectable otherwise. These results suggested that a marked decrease in viable cells without the liberation of verotoxin was observed in the feces of infected mice after fosfomycin was given orally in a massive dose.",
keywords = "E. coli O 157: H7, Fosfomycin, Mouse Infection, Verotoxin",
author = "I. Kobayashi and H. Muraoka and K. Matsuzaki and T. Saika and M. Nishida and H. Akita and S. Iwata and Y. Sato and K. Sunakawa",
year = "1998",
language = "English",
volume = "46",
pages = "445--449",
journal = "Japanese Journal of Chemotherapy",
issn = "1340-7007",
publisher = "Japan Society of Chemotherapy",
number = "11",

}

TY - JOUR

T1 - Therapeutic effect of fosfomycin against interstinal infection with Escherichia coli O157

T2 - H7 in a mouse model

AU - Kobayashi, I.

AU - Muraoka, H.

AU - Matsuzaki, K.

AU - Saika, T.

AU - Nishida, M.

AU - Akita, H.

AU - Iwata, S.

AU - Sato, Y.

AU - Sunakawa, K.

PY - 1998

Y1 - 1998

N2 - The therapeutic effect of fosfomycin at a large oral dose against intestinal infection with Escherichia coli O157: H7 was investigated in a mouse model previously described. Three ICR strain (IQI, germ free) mice aged 5 weeks were challenged orally with a verotoxin-producing strain NK2 of E. coli O157: H7. The high levels of viable cells, 3.0 x 1010-3.4 x 108 CFU/g, were excreted into the feces of the untreated mice for 3-10 days after bacterial challenge. Fosfomycin was given at an oral dose of 600 mg/kg twice a day for 6 days to 3 mice infected with E. coli O157: H7, beginning 3 days after the challenge, to investigate changes in viable cell counts and to measure fecal concentrations of fosfomycin. Results were that the viable cells decreased markedly, (from about 1010 CFU/g before dosing) to 103- 104 CFU/g on day 1 of dosing, and no viable cells were detected in the feces from day 2 of dosing onwards. During the period, no verotoxin was detected in fecal samples collected from all 6 test mice (including 3 control mice). Concentrations of fosfomycin in the feces after dosing were 34.6-47.4 μg/g in all the mice on day i of dosing, and 62.4 and 131.1 μg/g in 2 of the mice on day 6 after dosing, but nondetectable otherwise. These results suggested that a marked decrease in viable cells without the liberation of verotoxin was observed in the feces of infected mice after fosfomycin was given orally in a massive dose.

AB - The therapeutic effect of fosfomycin at a large oral dose against intestinal infection with Escherichia coli O157: H7 was investigated in a mouse model previously described. Three ICR strain (IQI, germ free) mice aged 5 weeks were challenged orally with a verotoxin-producing strain NK2 of E. coli O157: H7. The high levels of viable cells, 3.0 x 1010-3.4 x 108 CFU/g, were excreted into the feces of the untreated mice for 3-10 days after bacterial challenge. Fosfomycin was given at an oral dose of 600 mg/kg twice a day for 6 days to 3 mice infected with E. coli O157: H7, beginning 3 days after the challenge, to investigate changes in viable cell counts and to measure fecal concentrations of fosfomycin. Results were that the viable cells decreased markedly, (from about 1010 CFU/g before dosing) to 103- 104 CFU/g on day 1 of dosing, and no viable cells were detected in the feces from day 2 of dosing onwards. During the period, no verotoxin was detected in fecal samples collected from all 6 test mice (including 3 control mice). Concentrations of fosfomycin in the feces after dosing were 34.6-47.4 μg/g in all the mice on day i of dosing, and 62.4 and 131.1 μg/g in 2 of the mice on day 6 after dosing, but nondetectable otherwise. These results suggested that a marked decrease in viable cells without the liberation of verotoxin was observed in the feces of infected mice after fosfomycin was given orally in a massive dose.

KW - E. coli O 157: H7

KW - Fosfomycin

KW - Mouse Infection

KW - Verotoxin

UR - http://www.scopus.com/inward/record.url?scp=0032422072&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032422072&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0032422072

VL - 46

SP - 445

EP - 449

JO - Japanese Journal of Chemotherapy

JF - Japanese Journal of Chemotherapy

SN - 1340-7007

IS - 11

ER -